Today, we are excited to finally present Nexocyte™, our game-changing platform for tissue-based therapeutics and drug screening solutions, and to unveil our new company identity that solidifies our vision transform medicine and defeat serious disease.
"By introducing Nexocyte, we are laying the foundation for a new era in disease treatment with tissue-based therapy solutions, specifically targeting serious diseases that affect millions of patients worldwide. Nexocyte combines Fluicell's unique bioprinting technology with our cutting-edge expertise in tissue development, biomaterials and stem cell technology and is a powerful value proposition to pharmaceutical companies in search of the new frontier in tissue therapeutics.
With Nexocyte as the engine, we are intensifying our commitment to creating the next generation of tissue-based diabetes treatments, with the vision of creating a curative solution for everyone living with type 1 diabetes."
Carolina Trkulja, CEO Fluicell
Nexocyte is the culmination of 20 years of research and is a revolution in tissue technology that provides completely new opportunities for regenerative medicine and drug development. The platform combines our Biopixlar single-cell bioprinting technology with our expertise in tissue design, biomaterials and stem cell technology and enables us to develop transplantable tissues to treating serious diseases that affect millions of patients worldwide.
Together with the lauch of Nexocyte, we present a new identity that reinforces our vision to change how we treat disease and to create tissue-based solutions that transform regenerative medicine and drug development. The visual identity draws inspiration from the unique way in which Nexocyte and the Biopixlar technology enable us to create living tissues with cell level detail and precision.